Construction and validation of nomograms
TCGA, Cancer
BLADDER CANCER, CANCER
We developed nomograms based on the selected models containing LODDS in training cohort. As results, age, LODDS, T and M classification were incorporated into final nomogram for predicting OS (Figure Nomogram for OS of BC patients. (A) Prediction for 1‐, 3‐ and 5‐year OS of nomogram. Calibration plots for 1‐, 3‐ and 5‐year in training (B), internal validation (C) and TCGA cohorts (D). BC, bladder cancer; LODDS, log odds of positive lymph node;OS, overall survival; TCGA, The Cancer Genome Atlas.Nomogram for CSS of BC patients. (A) Prediction for 1‐, 3‐ and 5‐year CSS of nomogram. Calibration plots for 1‐, 3‐ and 5‐year in training (B), internal validation (C) and TCGA cohorts (D). BC, bladder cancer; CSS: cause‐specific survival; LODDS, log odds of positive lymph node; TCGA, The Cancer Genome Atlas.Evaluation of the nomograms for BC patients with AUC and DCA. The time‐dependent AUC for OS (A) and CSS (E) in three cohorts. Decision curves for predicting 1‐, 3‐ and 5‐year OS (B‐D) and CSS (F‐H) in training, internal validation and TCGA cohorts. Solid black line: assume no patients need clinical intervention, net benefit is zero. Solid color lines: assume all patients need receive clinical intervention. Dotted color lines: net benefits of the nomogram for predicting 1‐, 3‐ and 5‐year survival when patients receive intervention if predictions exceed the threshold. AUC, area under the curve; BC, bladder cancer; CSS, cause‐specific survival; DCA, decision curve analysis; OS, overall survival; ROC, receiver operating characteristic; TCGA, The Cancer Genome Atlas.